### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burde	en							
hours per response:	0.5							

1. Nume and Address of Reporting Leson		Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			<u></u>	X	Director	10% Owner				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	<b>-</b> x	Officer (give title below)	Other (specify below)				
			01/02/2020		See Remarks					
421 KIPLING	STREET									
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	vidual or Joint/Group Fili	ing (Check Applicable				
PALO ALTO	CA	94301		X	Form filed by One Re	eporting Person				
-			—		Form filed by More th Person	an One Reporting				
(City)	(State)	(Zip)								

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

lable I -	Non-Derivativ	e Securities A	Acquir	ed, I	Disposed	of, or I	Beneficially	Owned		-
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	01/02/2020		S <sup>(1)</sup>		11,091	D	\$32.5527 <sup>(2)</sup>	2,994,281	I	See footnote <sup>(3)</sup>
Common Stock	01/02/2020		S <sup>(1)</sup>		19,793	D	\$33.4129 <sup>(4)</sup>	2,974,488	I	See footnote <sup>(3)</sup>
Common Stock	01/02/2020		S <sup>(1)</sup>		5,077	D	\$34.1856 <sup>(5)</sup>	2,969,411	I	See footnote <sup>(3)</sup>
Common Stock	01/02/2020		S <sup>(1)</sup>		100	D	\$35.17	2,969,311	I	See footnote <sup>(3)</sup>
Common Stock	01/03/2020		S <sup>(1)</sup>		77,271	D	\$32.1428(6)	2,892,040	I	See footnote <sup>(3)</sup>
Common Stock	01/03/2020		S <sup>(1)</sup>		6,668	D	\$32.8809(7)	2,885,372	I	See footnote <sup>(3)</sup>
Common Stock								4,618,995	D	
Common Stock								400,375	I	See footnote <sup>(8)</sup>
Common Stock								927,686	I	See footnote <sup>(9)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(Month/Day/Year) 8) Securities Acquired Derivative Deri												
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any	Transa Code (		of Deriv Secu Acqu (A) or Dispo of (D)	of Expiration Date (Month/Day/Year) Securities Acquired A) or Disposed of (D) Instr. 3, 4		Amour Securi Under Deriva	nt of ties ying tive ty (Instr. 3	Derivative Security	derivative Securities Beneficially	Ownership Form: Direct (D)	of Indirect Beneficial Ownership	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019.

2. Represents the weighted average sale price of the shares sold from \$32.02 to \$33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7.

3. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his

pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from \$33.02 to \$34.01 per share.

5. Represents the weighted average sale price of the shares sold from \$34.02 to \$34.70 per share.

6. Represents the weighted average sale price of the shares sold from \$31.69 to \$32.68 per share.

7. Represents the weighted average sale price of the shares sold from \$32.695 to \$33.10 per share.

8. The shares are held by Neil Kumar LLC. The Reporting Person is a member of Neil Kumar LLC and shares voting, investment and dispositive power over the shares held by Neil Kumar LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

9. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his

pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Remarks:

Chief Executive Officer and President

<u>/s/ Brian Stephenson Attorney-</u> <u>in-Fact</u> 01/06/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.